Dentsply Sirona Cuts Full-Year Sales Outlook
The dental equipment maker lowered its 2026 net sales and adjusted earnings guidance on its third-quarter earnings call.
Updated on Nov. 16, 2026 in Corporate Finance

Dentsply Sirona lowered its full-year net sales expectation to approximately $3.5 billion and reduced adjusted EPS guidance to $1.20 to $1.30 during its third-quarter 2026 earnings call on November 5, 2026. Reported revenue fell 7.6%, with weakness driven by dental equipment lines.
Why it matters
The revised outlook reflects higher distribution costs and weaker equipment demand that cost reductions did not fully offset. Investors are watching whether the company can stabilize its core equipment business while continuing to invest in clinical education.
The company reported a 7.6% revenue decline as reported, and its adjusted EPS guidance was cut by roughly $0.20 at the midpoint. Adjusted guidance excludes a $0.17 one-time gain from tariff refunds, and the company did not detail the timing of future refunds.
The players
Dentsply Sirona
A publicly traded dental products manufacturer that supplies dental equipment, consumables and clinical education programs to dental practices worldwide.
The details
Management attributed the revenue weakness to dental equipment lines and cited higher distribution costs as a headwind. The company stated that its cost reductions did not fully offset these pressures, and it increased second-half 2026 North American clinical education investment to six times last year's level, including more than 160 endo courses. Wellspect Healthcare, which produces continence urinary catheter products, grew revenue 10% to $92 million during the quarter.
Timeline
- November 5, 2026: Third-quarter 2026 earnings call, where lowered guidance was announced.
- Second half 2026: Clinical education investment in North America runs at six times last year's level.
Market Dynamics
Dentsply Sirona's exclusion of a $0.17 one-time tariff refund from its adjusted EPS guidance means the cut to $1.20-$1.30 reflects underlying operations rather than trade-policy relief. This places the company's guidance reduction against the backdrop of tariff-related cost swings affecting U.S. medical equipment makers.
Shareholders and analysts holding Dentsply Sirona stock now face a lower adjusted EPS range of $1.20-$1.30 for 2026. The one-time tariff refund gain is excluded from that range, so investors should not assume it will recur when projecting future earnings.
The takeaway
Investors should separate one-time items such as tariff refunds from recurring operating results when evaluating guidance changes. Tracking distributor inventory levels and pricing discipline offers a clearer read on whether equipment demand is recovering.
Further reading
For broader context on how companies revise forecasts, see Corporate Finance coverage on Wisevoter.
Source note: This article includes information reported by The Motley Fool.






